News and Press Releases

All | News | Press | Recruitment

Recent | Archive

Valo Therapeutics Announces Clinical Trial Application Submission for German Phase I Oncology Clinical Trial of PeptiCRAd-1 with Pembrolizumab

Helsinki, Finland, 13th July 2021: Valo Therapeutics Limited (ValoTx), the developer of novel, adaptable immunotherapy platforms for cancer and infectious diseases, today announced it has submitted a clinical trial application (CTA) to the German Regulatory Agency, The Paul Ehrlich Institute (PEI) for a Phase I, first-in-human trial of PeptiCRAd-1 (Peptide-coated Conditionally Replicating Adenovirus 1) in three tumor types. The trial, to take place in Germany, will be an open-label, non-randomized, multi-centre study to evaluate the safety and immune activity of

13/7/21

Press Release

Valo Therapeutics Acquires University of Helsinki’s PeptiBAC Cancer and Infectious Disease Vaccination Technology

Potential for regional tuberculosis vaccines, novel personalized cancer vaccines, and improving checkpoint inhibition therapy

19/4/21

Press Release

Developing a Vaccine that Protects Against Covid-19 Variants

Despite the promise of several approved Covid-19 vaccines and the widespread rollout of vaccination programs around the world, recent mutations in the virus causing Covid-19 are raising concern. Can the current vaccines protect against different coronavirus variants?

15/3/21

Press Release

Valo Therapeutics and ImmunoScape Collaboration Identifies Immunogenic Peptides to Develop Pan Coronavirus Vaccine

Helsinki, Finland, 9 March 2021: Valo Therapeutics Limited (ValoTx), the developer of novel and adaptable immunotherapy platforms for cancer and infectious diseases, today announced the completion of a successful collaboration with the biotechnology company ImmunoScape ( Singapore and San Diego) to identify immunogenic peptides for the development of a pan Coronavirus vaccine. ImmunoScape has an immunomics-based technology platform that provides unprecedented insights into the human immune system. ImmunoScape’s Deep Immunomics platform enables the characterization of a patient’s immunome at ultra-high

9/3/21

Press Release

Valo Therapeutics Announces Board Appointment of Dr Mai-Britt Zocca

Dr Zocca is a biotech entrepreneur, founder and co-founder of several biotech spin-outs, and an expert in the development of immunotherapies for cancer

8/6/20

Press Release

Valo Therapeutics to Support Development of a Pan – Coronavirus Vaccine

Valo’s PeptiCRAd to coat non-replicating adenovirus expressing COVID-19 Spike Proteins and boost CD8+ T-cell immune response

27/4/20

Press Release

Targovax and Valo Therapeutics enter collaboration to develop RAS neoantigen coating of ONCOS viruses using PeptiCRAd technology

• Targovax and Valo Therapeutics intend to run pre-clinical proof-of-concept studies testing mutant RAS peptide coated ONCOS-102 adenovirus • If successful, the collaboration could lead to further development of a first-in-class mutant-RAS targeting oncolytic virus

21/4/20

Press Release

Valo Therapeutics Announces New Funding for Immuno-Oncology Trials

Funding to support GMP adenovirus manufacture for a First-in-Human basket clinical trial in melanoma, lung cancer, and triple negative breast cancer

6/2/20

Press Release

Valo Therapeutics acquires PeptiENV technology from the University of Helsinki

Broadening its oncolytic virus and tumour antigen-based immuno-oncology approach across enveloped viruses

2/9/19

Press Release

VALO THERAPEUTICS APPOINTS MICHAEL STEIN AS CHIEF EXECUTIVE OFFICER

Seasoned Healthcare Entrepreneur strengthens Management Team

17/6/19

Press Release

DNAtrix and Valo Therapeutics Enter into Strategic Partnership to Develop Peptide-Coated Oncolytic Viruses for Treating Cancer

HOUSTON and HELSINKI, Nov. 13, 2018 -- DNAtrix and Valo Therapeutics today announced an exclusive R&D collaboration to develop enhanced vaccines using DNAtrix's clinical stage viruses and Valo's proprietary antigenic peptide technology. DNAtrix's clinical stage oncolytic adenovirus platform and Valo's PeptiCRAd (Peptide-coated Conditionally Replicating Adenovirus) vaccination technology will be combined to generate a novel "armed oncolytic vaccine" for cancer therapy. While oncolytic adenoviruses alone offer a promising strategy to treat cancer, in combination with PeptiCRAd, superior and durable immunological protection

13/11/18

Press Release

Valo Therapeutics receives $4.6 million non-dilutive funding from Tekes, in order to accelerate development of a novel oncolytic virus-based cancer immunotherapy

Helsinki, Finland, July 4, 2017. The Finnish Funding Agency for Innovation, Tekes, has granted Valo Therapeutics a $4.6 million non-dilutive loan for the preparation of a Phase I trial of a novel oncolytic virus-based cancer immunotherapy called PeptiCRAd. Valo Therapeutics has now raised $8 million (including $3.4m seed capital in January 2017) towards its mission to provide cancer patients with less toxic and longer lasting therapeutic options. Valo Therapeutics aims at combining the PeptiCRAd technology with check point inhibitors in

4/7/17

Press Release

Valo Therapeutics closes seed fundraising round to develop a novel oncolytic virus-based cancer immunotherapy

A spin-out from the University of Helsinki, Valo Therapeutics is developing novel oncolytic viral vaccines for the treatment of multiple forms of cancer.

30/1/17

Press Release

Valo Therapeutics päätti siemenrahoituskierroksen kehittääkseen uutta onkolyyttiseen virukseen perustuvaa syövän immunoterapiaa

Valo Therapeutics, spin-out -yhtiö Helsingin yliopistosta, kehittää uutta onkolyyttiseen virukseen perustuvaa syövän immunoterapiaa, jolla voidaan hoitaa useita eri syöpätyyppejä.

30/1/17